Metsera Inc
MTSR70.500USD
0.000
Close 12/31, 16:00（ET）Quotes delayed by 15 min
7.41BMarket Cap
LossP/E TTM
More Details of Metsera Inc Company
Metsera, Inc. is a clinical-stage biopharmaceutical company, which is developing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies. The Company uses its proprietary MINT peptide library of nutrient stimulated hormone (NuSH) analog peptides alongside its half-life augmentation by lipid optimization (HALO) half-life extending platform and its MOMENTUM oral NuSH analog peptide delivery platform to deliver differentiated product candidates. Its product pipeline includes MET-097i, MET-233i, MET-233i + MET-097i, MET-097o/MET-224o, MET-002o, MET-034i, MET-067i, and MET-815i. The Company's additional pipeline includes MET-815i, MET-AMYo, MET-034i, MET-067i and MET-PYYi. MET-097i, its advanced product candidate, is a fully biased, monthly, subcutaneously injectable ultra-long acting GLP-1 RA. MET-233i is a subcutaneously injectable ultra-long-acting amylin analog, with enhanced solubility and miscibility with its other NuSH analog peptides.
Metsera Inc Info
Ticker SymbolMTSR
Company nameMetsera Inc
IPO dateJan 31, 2025
CEOMr. Christopher Whitten Bernard
Number of employees74
Security typeOrdinary Share
Fiscal year-endJan 31
Address3 World Trade Center
CityNEW YORK
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code10007
Phone12127846595
Websitehttps://metsera.com/
Ticker SymbolMTSR
IPO dateJan 31, 2025
CEOMr. Christopher Whitten Bernard
Company Executives of Metsera Inc
Name
Name/Position
Position
Shareholding
Change
,
,
--
--
Name
Name/Position
Position
Shareholding
Change
,
,
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
13.18%
The Vanguard Group, Inc.
5.52%
Janus Henderson Investors
5.08%
Alphabet, Inc.
3.59%
VR Adviser, LLC
3.56%
Other
69.06%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
13.18%
The Vanguard Group, Inc.
5.52%
Janus Henderson Investors
5.08%
Alphabet, Inc.
3.59%
VR Adviser, LLC
3.56%
Other
69.06%
Shareholder Types
Shareholders
Proportion
Investment Advisor
30.74%
Investment Advisor/Hedge Fund
14.21%
Venture Capital
10.07%
Hedge Fund
5.48%
Research Firm
0.82%
Bank and Trust
0.38%
Pension Fund
0.09%
Insurance Company
0.02%
Other
38.19%
Institutional Shareholding
Updated: an hour ago
Updated: an hour ago
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
256
65.13M
61.80%
-25.57M
2025Q3
191
90.76M
86.24%
+3.57M
2025Q2
133
95.51M
90.92%
+74.51M
2025Q1
104
95.08M
90.50%
+81.16M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
15.76M
14.97%
+590.52K
+3.89%
Jun 30, 2025
The Vanguard Group, Inc.
1.49M
1.41%
+19.69K
+1.34%
Jun 30, 2025
Janus Henderson Investors
3.39M
3.22%
+482.50K
+16.61%
Jun 30, 2025
Alphabet, Inc.
4.96M
4.71%
--
--
Jun 30, 2025
VR Adviser, LLC
3.75M
3.56%
--
--
Jun 30, 2025
Wellington Management Company, LLP
3.43M
3.26%
+1.03M
+42.69%
Jun 30, 2025
SB Global Advisers Ltd
4.82M
4.58%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.13M
1.07%
+21.77K
+1.96%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
First Trust Merger Arbitrage ETF
22.46%
Roundhill GLP-1 & Weight Loss ETF
4.57%
ProShares Merger ETF
3.14%
ALPS Medical Breakthroughs ETF
2.73%
Amplify Weight Loss Drug & Treatment ETF
1.68%
Direxion Daily S&P Biotech Bull 3X Shares
0.98%
Pacer WealthShield ETF
0.25%
BNY Mellon US Small Cap Core Equity ETF
0.17%
First Trust US Equity Opportunities ETF
0.15%
Global X Russell 2000 ETF
0.12%
View more
First Trust Merger Arbitrage ETF
Proportion22.46%
Roundhill GLP-1 & Weight Loss ETF
Proportion4.57%
ProShares Merger ETF
Proportion3.14%
ALPS Medical Breakthroughs ETF
Proportion2.73%
Amplify Weight Loss Drug & Treatment ETF
Proportion1.68%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.98%
Pacer WealthShield ETF
Proportion0.25%
BNY Mellon US Small Cap Core Equity ETF
Proportion0.17%
First Trust US Equity Opportunities ETF
Proportion0.15%
Global X Russell 2000 ETF
Proportion0.12%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Metsera Inc?
The top five shareholders of Metsera Inc are:
Fidelity Management & Research Company LLC holds 15.76M shares, accounting for 14.97% of the total shares.
The Vanguard Group, Inc. holds 1.49M shares, accounting for 1.41% of the total shares.
Janus Henderson Investors holds 3.39M shares, accounting for 3.22% of the total shares.
Alphabet, Inc. holds 4.96M shares, accounting for 4.71% of the total shares.
VR Adviser, LLC holds 3.75M shares, accounting for 3.56% of the total shares.
Fidelity Management & Research Company LLC holds 15.76M shares, accounting for 14.97% of the total shares.
The Vanguard Group, Inc. holds 1.49M shares, accounting for 1.41% of the total shares.
Janus Henderson Investors holds 3.39M shares, accounting for 3.22% of the total shares.
Alphabet, Inc. holds 4.96M shares, accounting for 4.71% of the total shares.
VR Adviser, LLC holds 3.75M shares, accounting for 3.56% of the total shares.
What are the top three shareholder types of Metsera Inc?
The top three shareholder types of Metsera Inc are:
Fidelity Management & Research Company LLC
The Vanguard Group, Inc.
Janus Henderson Investors
Fidelity Management & Research Company LLC
The Vanguard Group, Inc.
Janus Henderson Investors
How many institutions hold shares of Metsera Inc (MTSR)?
As of 2025Q4, 256 institutions hold shares of Metsera Inc, with a combined market value of approximately 65.13M, accounting for 61.80% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -24.44%.
What is the biggest source of revenue for Metsera Inc?
In --, the -- business generated the highest revenue for Metsera Inc, amounting to -- and accounting for --% of total revenue.
